Characterization of pyrimidine nucleoside phosphorylase ofMycoplasma hyorhinis: implications for the clinical efficacy of nucleoside analogues

The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2′-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes

(2011) Johan Vande Voorde et al.   BIOCHEMICAL PHARMACOLOGY

Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer

(2011) Cydney Urbanek et al.   BMC CANCER

Genome Analysis of a Mycoplasma hyorhinis Strain Derived from a Primary Human Melanoma Cell Line

(2011) J. D. Kornspan et al.   JOURNAL OF BACTERIOLOGY

Bacterial and fungal microflora in surgically removed lung cancer samples

(2011) Panagiotis Apostolou et al.   Journal of Cardiothoracic Surgery

Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside

(2011) Christopher McGuigan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mycoplasma hyorhinisinfection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells

(2010) Hua Yang et al.   BMC GASTROENTEROLOGY

Complete Genome Sequence of Mycoplasma hyorhinis Strain HUB-1

(2010) W. Liu et al.   JOURNAL OF BACTERIOLOGY

Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes

(2009) Sandra Liekens et al.   LANCET ONCOLOGY

Protein structure prediction on the Web: a case study using the Phyre server

(2009) Lawrence A Kelley et al.   Nature Protocols

Proteome Organization in a Genome-Reduced Bacterium

(2009) S. Kuhner et al.   SCIENCE

The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy

(2008) Annelies Bronckaers et al.   BIOCHEMICAL PHARMACOLOGY

Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors

(2008) Michael J. Overman et al.   CANCER INVESTIGATION

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors

(2008) Michael J. Overman et al.   INVESTIGATIONAL NEW DRUGS